Lipum AB Total Liabilities
Lipum AB total liabilities. Based on the latest financial reports, Lipum AB (LIPUM) has total liabilities worth Skr11.63 Million SEK (≈ $1.25 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Lipum AB (LIPUM) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Lipum AB (2017–2025)
Total liabilities of Lipum AB from 2017 to 2025. This chart illustrates how Lipum AB's total liabilities have evolved over time, based on quarterly financial data.
Lipum AB Competitors by Total Liabilities
The table below lists competitors of Lipum AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thirdeye Systems Ltd
TA:THES
|
Israel | ILA31.28 Million |
|
Laird Superfood Inc
NYSE MKT:LSF
|
USA | $7.76 Million |
|
Avante Logixx Inc
V:XX
|
Canada | CA$10.84 Million |
|
Phaos Technology Holdings (Cayman) Limited
NYSE MKT:POAS
|
USA | $3.90 Million |
|
PPAP Automotive Limited
NSE:PPAP
|
India | Rs3.31 Billion |
|
AIFORIA TECHNOLOGIES OYJ
F:L6J
|
Germany | €12.11 Million |
|
Globus Maritime Ltd
NASDAQ:GLBS
|
USA | $116.02 Million |
|
Compa Sibiu
RO:CMP
|
Romania | RON223.10 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Lipum AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Lipum AB.
Liquidity & Leverage Metrics
Lipum AB Total Liabilities Ratios Explained
Lipum AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lipum AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lipum AB (2017–2025)
The table below shows the annual total liabilities of Lipum AB from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr11.63 Million ≈ $1.25 Million |
-50.55% |
| 2024-12-31 | Skr23.51 Million ≈ $2.53 Million |
+211.91% |
| 2023-12-31 | Skr7.54 Million ≈ $811.21K |
+15.90% |
| 2022-12-31 | Skr6.50 Million ≈ $699.93K |
-70.14% |
| 2021-12-31 | Skr21.78 Million ≈ $2.34 Million |
+217.46% |
| 2020-12-31 | Skr6.86 Million ≈ $738.36K |
+309.56% |
| 2019-12-31 | Skr1.68 Million ≈ $180.28K |
-81.31% |
| 2018-12-31 | Skr8.96 Million ≈ $964.39K |
+1944.11% |
| 2017-12-31 | Skr438.40K ≈ $47.18K |
-- |
About Lipum AB
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a… Read more